Related Experiment Video
Updated: Mar 18, 2026

Protein Kinase C-delta Inhibitor Peptide Formulation using Gold Nanoparticles
Published on: March 9, 2019
Pharmaceutical patent law: the Canadian perspective.
1Gowling WLG (Canada) LLP, 160 Elgin Street Suite 2600, Ottawa, Ontario K2P 1C3, Canada.
This article reviews Canadian patent law for the pharmaceutical industry, covering patent application, enforcement, and recent legal developments. It also examines the influence of trade agreements on patentability requirements.
Area of Science:
- Intellectual Property Law
- Pharmaceutical Science
Background:
- Canadian patent law governs innovation and market exclusivity.
- The pharmaceutical industry relies heavily on patent protection for drug development.
- Understanding patentability is crucial for pharmaceutical companies.
Purpose of the Study:
- To provide an overview of the Canadian patent regime.
- To focus on issues pertinent to the pharmaceutical sector.
- To analyze recent case law and trade agreement impacts.
Main Methods:
- Review of Canadian patent legislation.
- Analysis of key court decisions on patentability.
- Examination of international trade agreements affecting patent law.
Main Results:
- Discussion of patent application processes, enforcement, and litigation.
- Overview of recent case law on novelty, obviousness, utility, and sufficiency.
- Assessment of trade agreements' influence on Canadian patent law.
Conclusions:
- Canadian patent law presents specific considerations for pharmaceutical innovations.
- Recent legal and trade developments necessitate ongoing review by the industry.
- Strategic understanding of patentability is vital for market access and R&D.
More Related Videos
10:17High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
Published on: April 23, 2019
09:30Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
Published on: March 17, 2023
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Pharmaceutical Equivalents
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
Drug Nomenclature